Studies Introducing Costimulation Blockade for Vascularized Composite Allografts in Nonhuman Primates

Vascularized composite allografts (VCAs) are technically feasible. Similar to other organ transplants, VCAs are hampered by the toxicity and incomplete efficacy associated with conventional immunosuppression. Complications attributable to calcineurin inhibitors remain prevalent in the clinical cases reported to date, and these loom particularly large given the nonlifesaving nature of VCAs. Additionally, acute rejection remains almost ubiquitous, albeit controllable with current agents. Costimulation blockade offers the potential to provide prophylaxis from rejection without the adverse consequences of calcineurin‐based regimens. In this study, we used a nonhuman‐primate model of VCA in conjunction with immunosuppressive regimens containing combinations of B7‐specific costimulation blockade with and without adhesion blockade with LFA3‐Ig to determine what adjunctive role these agents could play in VCA transplantation when combined with more conventional agents. Compared to tacrolimus, the addition of belatacept improved rejection free allograft survival. The combination with LFA3‐Ig reduced CD2hi memory T cells, however did not provide additional protection against allograft rejection and hindered protective immunity. Histology paralleled clinical histopathology and Banff grading. These data provide the basis for the study of costimulation blockade in VCA in a relevant preclinical model.

[1]  A. Mehta,et al.  Inhibition of αvβ6 Promotes Acute Renal Allograft Rejection in Nonhuman Primates , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  Geoffroy C. Sisk,et al.  Vascularized composite tissue allotransplantation – state of the art , 2013, Clinical transplantation.

[3]  Vikesh K. Singh,et al.  Sirolimus based immunosuppression is associated with need for early repeat therapeutic ERCP in liver transplant patients with anastomotic biliary stricture. , 2013, Annals of hepatology.

[4]  A. Mehta,et al.  Belatacept and Sirolimus Prolong Nonhuman Primate Renal Allograft Survival Without a Requirement for Memory T Cell Depletion , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  C. Larsen,et al.  Belatacept and Sirolimus Prolong Nonhuman Primate Islet Allograft Survival: Adverse Consequences of Concomitant Alefacept Therapy , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  B. Nashan,et al.  Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature , 2012, Transplantation.

[7]  L. Rostaing,et al.  Three‐Year Outcomes from BENEFIT, a Randomized, Active‐Controlled, Parallel‐Group Study in Adult Kidney Transplant Recipients , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  S. Schneeberger,et al.  Achievements and challenges in composite tissue allotransplantation , 2011, Transplant International.

[9]  P. Grimbert,et al.  Feasibility, Reproducibility, Risks and Benefits of Face Transplantation: A Prospective Study of Outcomes , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  A. Mehta,et al.  Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 Expression , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  F. Schuind,et al.  The International Registry on Hand and Composite Tissue Transplantation , 2010, Transplantation.

[12]  P. Cavadas,et al.  Improvement in renal function after late conversion to sirolimus-based immunosuppression in composite tissue allotransplantation. , 2010, Transplantation.

[13]  E. Rodriguez,et al.  Clinical Facial Composite Tissue Allotransplantation: A Review of the First Four Global Experiences and Future Implications , 2010, Plastic and reconstructive surgery.

[14]  J. Niezgoda,et al.  Impaired lower extremity wound healing secondary to sirolimus after kidney transplantation. , 2009, The journal of the American College of Certified Wound Specialists.

[15]  T. McCormick,et al.  Alefacept in the treatment of psoriasis. , 2008, Clinics in dermatology.

[16]  A. Kirk,et al.  The Banff 2007 Working Classification of Skin‐Containing Composite Tissue Allograft Pathology , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  M. Zembala,et al.  Surgical wound‐healing complications in heart transplant recipients treated with rapamycin , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[18]  A. Kirk,et al.  Composite Tissue Allotransplantation: Development of a Preclinical Model in Nonhuman Primates , 2005, Transplantation.

[19]  F. Schuind,et al.  The International Registry on Hand and Composite Tissue Transplantation , 2005, Transplantation.

[20]  P. Linsley,et al.  Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  D. Kahn,et al.  Effect of rapamycin on the healing of the bile duct. , 2005, Transplantation proceedings.

[22]  N. Kenyon,et al.  Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. , 2002, Diabetes.

[23]  Position paper on the initiation of clinical
trials of xenotransplantation
The American Society of Transplantation and The American Society of
Transplant Surgeons , 2000, Xenotransplantation.

[24]  T. Strom,et al.  Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance , 1999, Nature Medicine.

[25]  W. Buurman,et al.  Transplant International Official Journal of the European Society for Organ Transplantation , 1992, Springer Berlin Heidelberg.